Yes, molecular cytogenetics testing is mandatory for newly diagnosed AML patients.
Conventional cytogenetic analysis remains mandatory in the evaluation of suspected AML, and molecular cytogenetics (FISH) should be considered mandatory when conventional cytogenetic analysis fails 1, 2.
Why This Testing is Essential
The requirement for cytogenetic and molecular testing is driven by three critical factors affecting patient outcomes:
1. Risk Stratification Directly Impacts Survival
Cytogenetic abnormalities are among the most powerful independent prognostic factors in AML 1. They determine whether patients fall into favorable, intermediate, or adverse risk categories, which fundamentally changes treatment intensity and transplant decisions. Without this information, you cannot appropriately risk-stratify patients or make evidence-based treatment decisions.
2. Specific Testing Requirements
Conventional cytogenetics:
- Must evaluate at least 20 metaphases 2
- Identifies balanced translocations and inversions critical for diagnosis and prognosis 1
Molecular cytogenetics (FISH):
- Should be considered mandatory when conventional cytogenetics fails 2
- Detects cryptic aberrations that conventional karyotyping misses, including MLL/KMT2A rearrangements, inv(16), and chromosome 3 aberrations 2
Molecular studies (must be performed at diagnosis):
- FLT3 (ITD and TKD mutations) - should be performed immediately to allow timely initiation of FLT3 inhibitors 2
- NPM1 mutations 2
- CEBPA (double mutations) 2
- PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11 fusion genes 2
- TP53, RUNX1, ASXL1 mutations (classify patients to adverse ELN risk group) 2
- IDH1 and IDH2 mutations (identify patients for targeted inhibitors) 2
3. Genetic Abnormalities Override Morphology
The presence of AML-related recurrent genetic abnormalities overrules morphological uncertainties 2. This means cytogenetic testing is not just prognostic—it's diagnostic in certain contexts.
Common Pitfalls to Avoid
- Don't wait for cytogenetics to start FLT3 testing: FLT3 molecular studies should be performed immediately, not after cytogenetics return 2
- Don't assume normal cytogenetics means good prognosis: 40-50% of AML cases have normal karyotypes and require molecular studies to refine prognosis 3
- Don't skip FISH when karyotyping fails: Karyotype analysis may miss clinically significant cryptic aberrations 2
Practical Implementation
If next-generation sequencing (NGS) panels are available, they provide comprehensive prognostic and therapeutic information in a single test 2. However, even with NGS, conventional cytogenetics remains mandatory as it provides a complete genomic picture that cannot be fully replaced by targeted sequencing approaches 1.
The 2017 ELN recommendations from Blood and the 2020 ESMO Clinical Practice Guidelines both explicitly state that conventional cytogenetic analysis is mandatory, with molecular cytogenetics serving as a required backup when conventional methods fail 1, 2.